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barriers.
Study Design and Setting: Web-based survey of Directors of 45 UK Clinical Research Collaboration (UKCRC)eregistered CTUs.
Results: Twenty-three (51%) CTUs responded: Five (22%) of these had an established data sharing policy and eight (35%) specifically
requested consent to use patient data beyond the scope of the original trial. Fifteen (65%) CTUs had received requests for data, and seven
(30%) had made external requests for data in the previous 12 months. CTUs supported the need for increased data sharing activities
although concerns were raised about patient identification, misuse of data, and financial burden. Custodianship of clinical trial data and
requirements for a CTU to align its policy to their parent institutes were also raised. No CTUs supported the use of an open access model
for data sharing.
Conclusion: There is support within the publicly funded UKCRC-registered CTUs for data sharing, but many perceived barriers remain.
CTUs are currently using a variety of approaches and procedures for sharing data. This survey has informed further work, including develop-
ment of guidance for publicly funded CTUs, to promote good practice and facilitate data sharing.  2016 TheAuthors. Published by Elsevier
Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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4.0/).1. Introduction
Historically, many researchers have considered data
generated in the conduct of a clinical trial as ‘‘private prop-
erty’’ belonging to the trial sponsor or original research
group [1]. As a result, further use of the data has often been
restricted to those researchers, possibly limiting the
research potential of valuable data. Progress is being made,
and the potential added value of sharing clinical trial data is
becoming more widely accepted. In particular, the sharing
of patient-level data could enhance many research-related
activities [2,3]. Secondary analyses and meta-analysis of in-
dividual participant data (IPD) could reveal directions for
future research and reduce the requirement for further clin-
ical trials, and therapies could be made available to patients
more quickly [4,5].s article under the CC BY license (http://creativecommons.org/licenses/by/
18 C. Hopkins et al. / Journal of Clinical Epidemiology 70 (2016) 17e25What is new?
 Publicly funded Clinical Trial Units (CTUs) have a
crucial role to play in the sharing of individual
participant level data from clinical trials.
 There is a lack of information available on current
data sharing practice, level of support, and barriers
to data sharing within publicly funded CTUs.
 This study has demonstrated that there is general
support for clinical trial data sharing among pub-
licly funded CTUs.
 However, there are concerns amongst the commu-
nity about the potential misuse of data and the
resource implications of data sharing activities.
 Several publicly funded CTUs are already involved
with data sharing, but further guidance is now
needed to help increase this and identify good
practice.The incentives for sharing clinical trial data in conjunc-
tion with concerns of publication bias and selective report-
ing practices have led to significant growth in support for
initiatives that could lead to greater trial transparency, aim-
ing to promote open science, benefit the public’s health, and
reduce wasteful research [6e10]. Recently, focus on
sharing data from clinical trials has led to consideration
of how industry, regulatory bodies, and clinical trial funders
can amend their practices to facilitate clinical trial transpar-
ency. The AllTrials campaign [11] calls for all past and pre-
sent clinical trials to be registered and their full methods
and summary results reported and has the support of repre-
sentatives from regulatory bodies, industry, publishing
groups, research funders, and many others. The European
Medicines Agency (EMA) has recently released a policy
for ‘‘Publication and access to clinical trial data’’ [12],
and the Association of the British Pharmaceutical Industry,
the Institute of Medicine, and the European Forum for
Good Clinical Practice are among many groups to have
held workshops discussing sharing clinical trial data and
ensuring transparency [13e15]. The British Medical Jour-
nal (BMJ) strongly supports transparency and data sharing
with a policy stating that ‘‘from January 2013 trials of
drugs and medical devices will be considered for publica-
tion only if the authors commit to making the relevant ano-
nymized patient-level data available on reasonable request’’
[16]. Significant steps toward transparency are being made
by some pharmaceutical companies. The collaborative Web
site https://www.clinicalstudydatarequest.com/ provides a
route to request access to anonymized patient-level data
and supporting documents from multiple sponsors
[17,18]. Separately, the Johnson & Johnson agreement withthe Yale University Open Data Access (YODA) project
allows third party access to their data [19].
Much of the publicity surrounding the topic of clinical
trial data transparency has featured stakeholders involved
with commercially funded clinical trials. However, clinical
trials are also designed, coordinated, analyzed, and reported
by publicly funded sponsors. Indeed, 58% of intervention tri-
als registered in clinicaltrials.gov (October 2014) have
nonindustry sponsors, and they too have a duty to consider
procedures to make patient-level data available. Rathi et al.
[20] surveyed 317 trialists from a range of sectors to evaluate
levels of support and concerns associated with clinical trial
data sharing, and the Cochrane IPD Meta-analysis Methods
Group was surveyed in 2011 [21]. Both surveys demon-
strated that public sector researchers are generally in support
of making clinical trial data available. This is further evi-
denced by several examples of publicly funded clinical tria-
lists making data available through open access systems
(e.g., Virtual International Stroke Trials Archive [VISTA],
Alzheimer’s Disease Neuroimaging Initiative [ADNI], and
The National Institute of Diabetes and Digestive and Kidney
Diseases [NIDDK]) [22e24], by providing IPD for meta-
analysis (e.g., ACCENT database, INDANA) [25,26] and
as part of wider genetic data consortia (e.g., Biomarkers
Consortium, PRO-ACT) [27,28]. Despite this progress, ac-
cessing clinical trial data from publicly funded clinical trials
can sometimes be difficult, if not impossible, and further
steps are needed to encourage and facilitate future sharing.
The UK Clinical Research Collaboration (UKCRC)e
registered Clinical Trial Unit (CTU) network includes 45
publicly funded CTUs that design, conduct, analyze and
publish clinical trials across different diseases and settings.
The CTUs are notable in that they can be involved in both
sides of data sharing; requests for data are made to the units
from external researchers, and members within the units
can also be involved in requesting data from other sources.
The CTUs are a potential vehicle to facilitate data sharing
of publicly funded trials in the United Kingdom and could
provide a model of good practice for other publicly funded
trials. Therefore, we surveyed CTU directors to capture
current practice, identify perceived barriers, and explore
attitudes to help inform the development of guidance to
facilitate data sharing of publicly funded trials.2. Methods
2.1. Survey instrument development
We developed a 47-item questionnaire as part of an
MRC-funded project. Questions were selected by the
research team using their expertise and experiences of data
sharing activities. The survey was developed and conducted
online using SelectSurvey.NET. The complete survey is
provided as Supplementary Material/Appendix at www.
jclinepi.com. A brief synopsis and link to the survey was
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2014. E-mail reminders were sent after 2, 4, and 6 weeks.
Multiple responses from the same unit were combined
where complementary; otherwise, the response of the most
senior CTU member was used.
The questionnaire took approximately 15 minutes to
complete. Ethical approval was obtained from the Univer-
sity of Liverpool Research Ethics Committee. As the sur-
vey was conducted online, completion was regarded as
consent to participate.
2.2. Survey domains
Multiple choice, Likert scale, and free-text questions
covered the areas of:
1. Current practice
2. Custodian experience
3. Requester experience
4. Future perspective
5. Standards and awareness
6. Models for data sharing
7. Requirements and potential problems2.3. Response analysis
Free-text responses were reviewed and categorized by
two of the research team (C.H. and C.T.S.) with categoriza-
tions compared and agreed. Results were summarized using
descriptive statistics.Fig. 1. Current practice regarding data sharing policy and consent
from participants to share their data. *No policy includes seven CTUs
with no immediate intention to develop a policy and 11 CTUs with a
policy in development. CTUs, Clinical Trial Units.3. Results
There were 24 responses from 23 (51%) registered CTUs
across the United Kingdom (two responses were received
from the same CTU). Three of the responders provided par-
tial information and have therefore only been included in
relevant sections of the results. From 24 responses, the major-
ity (71%) were completed by the CTU Director or Deputy
Director with seven (29%) completed by delegated members
of the CTUs including statisticians, operations managers, data
managers, and trial managers. Responding CTUs conducted
trials in many diseases, all trial phases, and included clinical
trials of investigational medicinal products (CTIMPs) and
non-CTIMP trials; there were no specific trial phases, disease
types, or methodological research areas that were underrepre-
sented in the survey compared with nonresponding CTUs.
3.1. Current practice
Five of the 23 CTUs (22%) had an established Data
Sharing Policy, 11 (48%) had a policy in development,
but seven (30%) had no immediate intention of developing
a policy.
Eight (35%) CTUs indicated that consent is generally
sought from participants in clinical trials for their data tobe used outside the original scope of trials (Fig. 1). Howev-
er, a standard phrase was not being used across the CTUs.
Examples of text used include: ‘‘agree to allow any infor-
mation or results arising from this study to be used for
health care and/or further medical research on the under-
standing that my identity will remain anonymous wherever
possible’’; consent for ‘‘medical data to be collected for this
study and may be used to develop new research and that
data protection regulations will be observed’’; ‘‘used for
future research and to be transferred to research institutes
within the UK’’; consent for separate blood samples to be
‘‘anonymized and stored for infection and immunity-
related research in the future’’; consent for ‘‘participants
to be contacted independently by other researchers to take
part in research within the same disease area.’’
Of the 15 (65%) CTUs that do not currently specifically
request consent for patient data to be used beyond the scope
of the original trial, 12 (80%) would be prepared to request
broader consent in the future (one only if the CTU signed
up to a central repository in future), but two (13%) would
not, giving the following reasons; ‘‘This should not be CTU
policydneeds discussion and approval of other parties’’ and
‘‘This should be a condition of ethical approval or fundingd
the CTU only handles data on a subset of studies and this is a
much wider issue.’’ One CTU did not provide a response.3.2. CTU experience of sharing data
Fifteen (65%) CTUs had received at least one request for
data in the previous 12 months. Most commonly, two re-
quests had been received, but four CTUs had received at
least five data requests. Institutes of higher education were
the most common requester of data (n 5 10), followed by
NHS Trust/Clinician (n 5 6), independent researcher
(n 5 5), and industry (n 5 4). The most common reason
for requesting data was for meta-analysis. No recent re-
quests had been refused, although some were only partially
fulfilled due to conflict with other research projects or
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ity and originality of research proposal, verification of
governance, timing of request, and labor intensity of fulfill-
ing the request were the most common considerations (re-
ported by at least two-thirds of the CTUs) when
reviewing requests for data from the CTU (Fig. 2). There
were no reported issues with providing the data in the
format that had been requested.
Fourteen (93%) of the 15 CTUs that received requests
had also received a research proposal outlining the purpose
of the data request for at least one request, but only nine
(60%) CTUs used a data sharing agreement. Six (40%)
CTUs received ‘‘Requester credentials to signify compe-
tence to analyze data,’’ and five (33%) had received ‘‘assur-
ances that there would be no attempts to retrospectively
identify patients’’ as part of their data sharing process.
CTUs that had been involved with sharing data were
asked about the resources required and whether certain ac-
tivities were more difficult for older trials (O5 years old)
compared with more recent trials. The majority (93%)
stated that the location and preparation of the data were
resource intensive (defined in our survey as more than half
a day to complete) and this was the most frequently cited
activity (n5 6, 40%) felt to be more difficult for older trials
compared with more recently completed trials. Ten (67%)
CTUs described the anonymization of data as ‘‘not likely
to be resource intensive,’’ and only two (13%) felt that this
would be more difficult for older trials. Reviewing requests
for validity was considered more difficult by three (20%)Fig. 2. Considerations when reviewing requests for data as reported by 15 C
of responses !15 as at least one CTU did not respond. CTUs, Clinical TriaCTUs, and two (13%) described generating data sharing
agreements as more difficult for historical data.3.3. CTU experiences of requesting external data
Of all 23 responding CTUs, seven (30%) had made an
external request for data in the last 12 months. Six of these
provided additional information about the external
requests; four CTUs (67%) had made two requests, and
two CTUs (33%) had made more than five requests. These
requests had been made to: ‘‘Institute of higher education’’
(n 5 3), ‘‘Industry’’ (n 5 2), ‘‘NHS Trust/Clinician’’
(n 5 2), ‘‘Independent researcher’’ (n 5 2), and ‘‘Other’’
[‘‘NHS DatadInformation Centre’’ (n 5 1) and ‘‘Health
and Social Care Information Centre’’ (n 5 1)]. All six
CTUs had made successful requests, and data had been pro-
vided either completely (n 5 4, 67%) or partially (n 5 2,
33%). There was considerable variation in the time taken
between their initial request and the provision of data
ranging from a few weeks to over a year. Reasons given
for making the data requests were provided by the six
CTUs as: meta-analysis (n 5 4), follow-up of trial partici-
pants (n 5 2), methodological research (n 5 1), and feasi-
bility of setting up registry (n 5 1). All six CTUs had been
required to submit a research proposal and data sharing
agreement, and some were required to provide assurances
they would not attempt to retrospectively identify patients
(n 5 3) and provide credentials or proof of competency
to analyze the data being requested (n 5 2).TUs that had received a request in the past 12 months. *Total number
l Units.
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3.4.1. Standards and awareness
Twenty-one CTUs rated their knowledge of various data
sharing initiatives, policies, and incentives. The AllTrials
campaign was the most well known, with 13 (65%) re-
sponders indicating they had ‘‘excellent’’ or ‘‘good’’
knowledge of the campaign (one nonresponse). The YODA
initiative was least well known with 18 (86%) ‘‘unaware’’
of the project. Responders had some awareness of the draft
EMA Policy, clinicalstudydatarequest.com Web site, the
BMJ policy on data sharing, and data sharing policies of
clinical trial funders (Fig. 3). Examples of other initiatives
or policies that respondents were aware of included the
‘‘new EU Clinical Trial regulation,’’ ‘‘NHS Information
Governance and the NHS Consortium,’’ ‘‘US Institute of
Medicine,’’ ‘‘PLOS,’’ and ‘‘NIH’’ policies.
As the use of common data standards across trials could
simplify data sharing, the CTUs were asked if there were
any data standards commonly used within the unit. Eleven
of 21 (52%) CTUs stated that they apply standard formats
for their electronic data. MedDRA (Medical Dictionary for
Regulatory Activities) was the most frequently named stan-
dard (n 5 6), but CDISC (Clinical Data Interchange
Standards Consortium) (n 5 2) and CTCAE (Common Ter-
minology Criteria for Adverse Events) v4.0 (n 5 1) were
also mentioned.
Twelve of 21 CTUs (57%) would be prepared to adopt a
standard data sharing policy (standardized for the UKCRC
CTUs as a minimum), but nine (43%) indicated that there
were specific reasons or external influences that would pre-
vent their CTU adopting a standard data sharing policyd
these were categorized as: process cannot be standardized;
standardizing data too complicated; overarching university
and NHS policy on data sharing; variety of governanceFig. 3. Awareness of various data sharing initiatives and policies. *To-
tal response is!21 because CTUs failed to provide a response or re-
sponded N/A. YODA, Yale University Open Data Access; EMA,
European Medicines Agency; BMJ, British Medical Journal; CTUs,
Clinical Trial Units.structures for different data types; conditions to involve
the trial team in review of data request and include trial
investigator on publication; burden on original researchers;
patent/IP issues; ownership of data; misuse/incorrect
secondary analysis; participant consent; ethical approval;
logistical; and cost implications. Fourteen of 20 (70%)
CTUs would be prepared, in principle, to transfer data to
a central repository assuming it was legal and ethical. Many
used a free-text box to indicate associated concerns about
confidentiality, funding, and the issue of data ownership.
3.4.2. Models for data sharing
An ‘‘internal review’’ model, in which the data custo-
dian would review and assess a request based on criteria
such as scientific soundness of the proposal or competence
of the requestor to perform the specific proposed analyses,
was considered the most suitable model for granting access
to data (n 5 15 of 20, 75%). Five (25%) CTUs preferred a
‘‘learned intermediary’’ model with requests for data re-
viewed independently by a review panel. Notably, none
of the CTUs considered an ‘‘open access’’ model with no
required approval process as ‘‘most suitable’’ (Fig. 4).
CTUs commonly considered (n 5 9 of 19, 47%) access
through ‘‘restricted interface’’ model as most suitable for
data provision; the data custodian maintains possession
but grants access to an external requestor through a specific
secure interface with restrictions on data download. Five
(26%) supported an approach whereby data would be
uploaded to and downloaded from a central independent
repository, and an equal number (n 5 5, 26%) viewed
‘‘direct transfer’’ of data to external parties without a(n
=2
0)
(b
)
(n
=
Fig. 4. Models rated ‘‘Most suitable’’ by responding CTUs. aData stor-
age and transfer. Direct transfer: data transferred to external users for
secondary analyses. Restricted interface: data remain with the data
custodian, but access is granted for external users to analyze data
through a specific interface. Central repository: data are uploaded
to, and downloaded from, a central independent repository. bApproval
process. Learned intermediary: an Independent Review Board reviews
requests and judges them based on criteria such as science, benefit-
risk analysis, and competence of the requestor to perform the speci-
fied analyses. Internal review: specific detailed requests are placed
with the custodian who assesses the request based on science,
benefit-risk analysis, and competence of the requestor to perform
the specified analyses. Open access: no approval required, data avail-
able for any user to access. CTUs, Clinical Trial Units.
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a further suggestion for ‘‘controlled access with active
engagement from trial team as research partners.’’
Twenty-one CTUs provided opinion about the most
appropriate time for making data available at the end of a
trial; 10 (48%) CTUs selected ‘‘At any time after the trial
team have completed all analyses and secondary explor-
atory analyses’’; 1 (5%) selected ‘‘As soon as final analysis
is complete’’; 2 (10%) chose ‘‘within 12 months of last
patient last visit’’; 1 (5%) chose ‘‘within 24 months of last
patient last visit’’; 6 (29%) CTUs provided free-text re-
sponses categorized as: timing would vary by trial [2]; after
the trial, results have been published [4]. One (5%) pro-
vided a data sharing policy which suggested a period of
exclusivity determined on a per trial basis (generally a min-
imum of 5 years from last patient last visit).
3.4.3. Potential problems
Twenty CTUs provided at least one response to a Likert
scale question (Fig. 5) addressing levels of concern on spe-
cific topics. The risk of incorrect secondary analyses and
misuse of data was of greatest concern with all but one
CTU stating they were moderately (n 5 7 of 20, 35%) or
very concerned (n 5 12 of 20, 60%), and most CTUs were
moderately (n 5 6 of 18, 33%) or very concerned (n 5 8 of
18, 44%) about the resource implications of sharing data.
CTUs were fairly evenly split across being very (n 5 7
of 20, 35%), moderately (n 5 6 of 20, 30%), or not very
concerned (n 5 7 of 20, 35%) about the loss of IP/ability
to publish. The ‘‘Identification of patients’’ and ‘‘additional
consent requirements’’ split the CTU opinion with approx-
imately half being ‘‘very’’ or ‘‘moderately’’ concerned and
the other half ‘‘not very’’ or ‘‘not at all’’ concerned. Some
‘‘Other’’ concerns were raised by three CTUs, specifically
the qualifications of applicants to analyze data, repository
security, patent protection, and potential impact on future
trial recruitment.Fig. 5. Level of concern about frequently raised barriers to making full
clinical trial data available on a controlled access platform. *Total
response was !20 because CTUs failed to provide a response or re-
sponded N/A. CTUs, Clinical Trial Units.CTUs were asked to indicate problems foreseen if all
data (including IPD) were to be published on a controlled
access platform. Eleven of 23 (48%) CTUs raised concerns
about time and resource implications of making data sets
available (n 5 6), getting all CTUs on board with a central
repository or standard data formats (n 5 4), how to deal
with subsets of patients withdrawing consent or not
providing it in the first place (n 5 3), the right of the spon-
sors or investigators to maintain rights over the use of the
data and to be acknowledged appropriately where data
are shared (n 5 4), and the risks of ‘‘bad research’’ both
to the original research group and patients (n 5 3).4. Discussion
This survey explores the data sharing views and experi-
ences of publicly funded CTUs in the United Kingdom.
The media attention that has surrounded the issue of clinical
trial data sharing within the last few years has mostly
focused on CTIMPs conducted within the pharmaceutical in-
dustry, but most of the issues, and the need to share data,
apply equally to publicly funded clinical trials. The CTUs
that responded to this survey are fundamentally different to
the pharmaceutical industry. They are involved in a diverse
range of trials including CTIMPs, device trials, surgical tri-
als, pragmatic trials, and observational studies. They do
not set out to make a profit from the sale of the interventions
being investigated, and trials within their portfolio are typi-
cally funded by public or charitable organizations. This often
creates complex sponsorship arrangements that may intro-
duce a level of ambiguity about ownership and responsibil-
ities for sharing the data generated in the clinical trial.
Publicly funded CTUs may also be linked to, or be part
of, parent organizations such as Universities or NHS Trusts,
and they may also conduct clinical trials in collaboration
with industry, hence, may need to consider these overarching
data sharing requirements in addition to those of the CTU,
the funder, potential journal, and any relevant regulatory re-
quirements. We would therefore strongly recommend that
the issue of data sharing is explicitly and thoroughly dis-
cussed between stakeholders during the planning of a pub-
licly funded trial to agree roles and responsibilities.
Indeed, we fully support the recommendation in the SPIRIT
2013 checklist that a dissemination policy should be
described in the trial protocol, with specific reference to
‘‘Plans, if any, for granting public access to the full protocol,
participant-level data set, and statistical code’’ [29].
Our survey showed a variety of attitudes toward data
sharing and different levels of activity and knowledge about
current data sharing initiatives. CTUs may not yet have
developed their procedures for sharing data due to a low de-
mand and inadequate resources. However, if CTUs were to
take a more proactive role in sharing data, awareness of the
wealth and potential value of the data that are available
could be increased. Of course this would have a resource
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rier for publicly funded CTUs. Funds may be provided to a
sponsor to facilitate data sharing in future trials, but histor-
ically, there has been no provision to cover costs of wider
data dissemination. Trialists now need to plan ahead for this
and include appropriate costs for data set preparation and
sharing in the same way as may be done for open access
publication or archiving trial data.
Consent from patients to share anonymized data is often
viewed as a prerequisite for data sharing, and one simple
approach to remove this perceived barrier for future trials
would be to actively seek consent from patients for this pur-
pose. Our survey suggests that only a minority of publicly
funded CTUs currently request consent for sharing data in
their trials, yet most CTUs were supportive of a move
toward such an approach. Furthermore, it is worth
mentioning that even if explicit consent to share anony-
mized data has not been requested from patients in ongoing
or completed trials, this does not preclude the sharing of
anonymized data; the Data Protection Act no longer applies
to data from deceased participants or data anonymized such
that the individual is no longer identifiable [30]. As an
example of this, the International Stroke Trial Collaborative
Group has made the data from their publicly funded clinical
trial publically available [22]. They note that ‘‘Consent for
publication of raw data was not obtained from participants’’
and because ‘‘the data set is fully anonymous,’’ they present
the view that ‘‘publication of the data set clearly presents
no material risk to confidentiality of study participants.’’
Those CTUs that had been approached for data in the last
12 months had provided data in all instances, albeit using
different, possibly ad hoc, approaches. Adoption of a stan-
dard procedure, or at least some common principles across
the CTUs, would greatly facilitate data sharing. The concept
of a clinical trial data repository that CTUs could transfer
data to was met positively, although there were differing
opinions about the format this repository should take demon-
strating the difficulty of a ‘‘one size fits all’’ approach.
Nevertheless, not one CTU felt that an open access approach
would be appropriate, the risks of bad research resulting
from poor secondary analyses or incorrect replication of pri-
mary analyses, and risks of patient identification, could be
mitigated through a controlled access system with data re-
quests supported by evidence of the research team’s exper-
tise and a research plan providing details of proposed
analyses. This practice has already been adopted by some
CTUs and requesting this information or having to provide
it does not seem to present a barrier to sharing activities.
Furthermore, ensuring that the data sets are fully annotated
and accompanied by all associated trial documentation such
as the protocol and blank Case Report Forms should further
minimize the possibility of conflicting results arising from
replicated analyses. If reanalysis of the same data did pro-
duce conflicting results, then this should firstly be discussed
with the original team, and if discrepancies remain, this in-
formation should of course be made publicly available.Sharing IPD from clinical trials is only one part of a
wider move toward ‘‘open science’’ that promotes open
access to journal articles, protocols, source code, and data.
Some may criticize an approach of sharing IPD with re-
searchers within a controlled system as not being ‘‘open’’
enough and may advocate data being openly available for
all to access without restriction. The clinical trials commu-
nity must ensure that all reasonable precautions are taken to
protect the privacy and confidentiality of trial participants
and this should always be the overriding consideration.
Taking unnecessary risks could lead to more harm than
good, and we support the use of a controlled access
approach as discussed by Sydes et al. [31].
4.1. Limitations of study
This survey was limited to UKCRC-registered CTUs and
may not necessarily be representative of all UK CTUs or or-
ganizations that conduct publicly funded trials. It was tar-
geted at CTU Directors but was completed by delegates in
some cases. As the survey addressed current practices within
the CTUs, there should not have been any impact of the re-
sponses being provided by someone other than the Director.
However, it is possible that responses represent a partly po-
litical view rather than the personal opinion of scientists. The
survey was short and simple, but only 51% of invitees pro-
vided useable responses; this level of response is typical of
Web-based surveys [20,32]. Reminders were sent regularly
by e-mail, but more responses might have been received
had follow-up occurred via telephone or if the survey re-
mained open for longer. We feel that the responses provide
a good representation of the UK stakeholder group; there
was no clear underrepresentation of any particular subset
of CTUs as a wide spread of phases, trial types, disease
areas, and unit sizes were represented among the responding
CTUs. Open questions allowing free-text answers enabled
responders to present additional issues, concerns, and sug-
gestions that may have been shared by other responders
had they been presented as options within the original sur-
vey. Our threshold for defining ‘‘resourceeintensive’’ one
half-day (i.e., 4 hours) was too low.
4.2. Future directions
The information gathered indicates that there is general
support for clinical trial data sharing within these publicly
funded CTUs, but there are several perceived barriers that
may be preventing initiatives from moving forward. This
information has been used to inform the development of
good practice guidance for publicly funded CTUs to
encourage future data sharing [33].
4.3. Conclusions
Sharing clinical trial data is at the forefront ofmany discus-
sions by regulatory bodies, research funders, and the pharma-
ceutical industry with an aim to increase transparency and
24 C. Hopkins et al. / Journal of Clinical Epidemiology 70 (2016) 17e25facilitate efficiency and advances in research. Publicly funded
CTUs have an important role to play in this arena. The wealth
of experience andknowledgewithin theunits could help estab-
lish an infrastructure to facilitate data sharing and improve the
use of publicly funded clinical trial data for the public good.
Action is now needed to focus efforts toward facilitating
further clinical trial data sharing and developing good practice
for data sharing in publicly funded CTUs.Acknowledgments
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